Catalyst Pharmaceuticals, Inc. (CPRX) BofA Securities CNS Therapeutics Virtual Conference 2025 December 8, 2025 12:35 PM EST
Company Participants
Richard John Daly – President, CEO & Director
Conference Call Participants
Jason Gerberry – BofA Securities, Research Division
Pavan Patel – BofA Securities, Research Division
Presentation
Operator
Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Jason Gerberry.
Jason Gerberry
BofA Securities, Research Division
Good day, everybody, and thanks for joining us at the BofA virtual CNS conference. My name is Jason Gerberry I’m one of the biotech analysts here, and I’m joined by Pavan Patel, who’s one of my colleagues who helps with Catalyst Pharma. Catalyst Pharma is our next company presenter and — Rich Daly, CEO. So Rich, thanks so much for joining us and giving us the latest update on Catalyst.
Richard John Daly
President, CEO & Director
Jason, thanks for having us. I really appreciate it and looking forward to the conversation. So thank you.
Question-and-Answer Session
Jason Gerberry
BofA Securities, Research Division
So maybe just starting with kind of the overarching BD in licensing, that’s obviously kind of core to what you do in building out the business. And you had sort of a stopgap product with FYCOMPA, but your 2 main assets for kind of the longer-term are AGAMREE and FIRDAPSE. And so how important is it for you to get a resolution with FIRDAPSE IP before you deploy capital in a more significant way? Maybe just talk about the importance of doing a deal in 2026 as a priority. Maybe we can start there and then delve into additional questions.
Richard John Daly
President, CEO & Director
Sure. So we feel like with the acquisition or the arrangement with the AGAMREE
Read the full article here